Precipio Inc Stock Price, News & Analysis

Precipio, Inc. (PRPO) will host a Q3-2022 shareholder update call on November 14th, 2022 at 5:00 PM ET, discussing updates on its core businesses. Participants can join via phone or pre-register for access. A replay will be available approximately 24 hours later. Precipio focuses on improving diagnostic accuracy in cancer treatment, leveraging collaborations with academic institutions. The press release includes forward-looking statements and advises that results may differ from expectations due to various risks, including those related to COVID-19.

On September 15, 2022, Precipio (NASDAQ: PRPO) announced a new distribution agreement for its HemeScreen platform, targeting a customer segment with over $100 million in market potential. This collaboration will expand Precipio's reach, as the distributor's sales team will promote HemeScreen to numerous healthcare accounts. The company aims for substantial growth in customer base and revenues, backed by this and previous distribution agreements, with expectations of increased inquiries and scheduled meetings with potential clients.

Precipio, Inc. (NASDAQ: PRPO) announces the appointment of Sharon Robins as Senior Director of Laboratory & Hospital Sales. Robins, with extensive experience from Qiagen, brings a proven track record of managing substantial revenues, including over $100M annually. This strategic hire aligns with the launch of HemeScreen in partnership with ThermoFisher, aiming for $10M in first-year revenues. The company emphasizes its commitment to improving cancer diagnostics and aims for robust growth in the upcoming year.

Precipio, Inc. (NASDAQ: PRPO) has launched its second-generation HemeScreen panels, streamlining cancer diagnostic processes. The new 1-step assay eliminates the previous 2-step confirmation, allowing same-day test results within about 3 hours. This upgrade not only accelerates turnaround time but also reduces bench work by 25%, saving laboratories time and costs. Preliminary discussions suggest strong customer interest in upgrading to this enhanced version, which has been clinically validated in Precipio’s certified lab. The firm aims to lead the market in cancer diagnostics.

Precipio, Inc. (NASDAQ: PRPO) is set to launch a nationwide sales effort for its HemeScreen product, utilizing over 250 sales representatives from AmerisourceBergen, ThermoFisher, and other distributors. With a market potential of approximately $0.5 billion, the company has appointed Toni-Ann Mills as Senior Director for Learning & Development to oversee the training of these sales teams. Mills, with over 20 years of experience in learning and development, aims to enhance the effectiveness of sales efforts and improve the product’s market presence.

Precipio, Inc. (NASDAQ: PRPO) has scheduled its Q2-2022 shareholder update conference call for August 15, 2022, at 5:00 PM EST. The call will provide insights into the company's core businesses and progress. Interested participants can join by calling 844-695-5519 or international callers at 1-412-902-6760. Pre-registration is available for a direct dial-in option. The update aims to address shareholder inquiries regarding Precipio's diagnostic innovations and collaborations in cancer diagnostics, emphasizing its commitment to improving diagnostic accuracy.

Precipio, Inc. (NASDAQ: PRPO) has entered into a distribution agreement with Fisher Healthcare, a division of Thermo Fisher Scientific, to expand the reach of its proprietary HemeScreen assays to laboratories across the U.S. This strategic partnership leverages Fisher Healthcare's extensive sales channels, allowing Precipio to enhance product accessibility and drive revenue growth. Precipio's HemeScreen technology is noted for its accuracy, reduced turnaround times, and cost-effectiveness, aligning with the needs of laboratories.

Precipio, Inc. (NASDAQ:PRPO) announced the adjournment of its 2022 Annual Meeting of Stockholders due to insufficient quorum, with only 49% participation from stockholders. The meeting has been rescheduled for July 5, 2022, at 10:00 a.m. EDT. Despite the adjournment, over 89% of received votes favored the proposed measures. Stockholders are encouraged to vote to enable the company to focus on growth. For inquiries regarding the meeting, stockholders can reach out via designated contact methods.

Precipio, Inc. (NASDAQ: PRPO) announced the appointment of Keith Meadors as Senior Vice President of its Products Division on June 13, 2022. Meadors brings over 30 years of executive experience in healthcare, most recently with Fresenius Kabi, where he expanded product offerings significantly. He has a history of driving revenue growth and product visibility. CEO Ilan Danieli expressed enthusiasm about Meadors’ expertise, highlighting its importance for the company’s potential. Precipio focuses on specialty cancer diagnostics with proprietary products.